Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjus...
Psyence Biomedical Ltd. - Ordinary Shares (PBM)
Company Research
Source: Financial Post
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025 NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“ Psyence Group “) (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) (“ PBM ” or “ Psyence Biomed “) yesterday announced the recruitment of Perth, Australia-based Empax Center as the second trial site for Psyence's Biomed ongoing Phase IIb clinical trial of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care. According to Dr. Clive Ward-Able, Medical Director of Psyence Biomed, “Having Empax Center as our second clinical trial site adds a cutting-edge facil
Show less
Read more
Impact Snapshot
Event Time:
PBM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBM alerts
High impacting Psyence Biomedical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PBM
News
- Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical TrialGlobeNewswire
- Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial [Yahoo! Finance]Yahoo! Finance
- Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations [Canadian Business Journal (Canada)]Canadian Business Journal
- Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligationsGlobeNewswire
PBM
Sec Filings
- 12/20/24 - Form F-1
- 12/19/24 - Form 6-K
- 12/18/24 - Form 6-K
- PBM's page on the SEC website